Format

Send to

Choose Destination
Mod Pathol. 2019 Dec 4. doi: 10.1038/s41379-019-0418-2. [Epub ahead of print]

Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer.

Author information

1
Institute for Cancer Genetics and Informatics, Oslo University Hospital, NO-0424, Oslo, Norway.
2
Department of Pathology, Oslo University Hospital, NO-0424, Oslo, Norway.
3
Department of Informatics, University of Oslo, NO-0316, Oslo, Norway.
4
Research Department of Pathology, University College London Medical School, London, WX1E 6DE, UK.
5
Institute for Cancer Genetics and Informatics, Oslo University Hospital, NO-0424, Oslo, Norway. hdaniels@labmed.uio.no.
6
Department of Informatics, University of Oslo, NO-0316, Oslo, Norway. hdaniels@labmed.uio.no.
7
Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 9DU, UK. hdaniels@labmed.uio.no.

Abstract

The mitotic checkpoint protein BUB3, cyclin B1 (CCNB1) and pituitary tumor-transforming 1 (PTTG1) regulates cell division, and are sparsely studied in prostate cancer. Deregulation of these genes can lead to genomic instability, a characteristic of more aggressive tumors. We aimed to determine the expression levels of BUB3, CCNB1, and PTTG1 as potential prognostic markers of recurrence after radical prostatectomy. Protein levels were determined by immunohistochemistry on three formalin-fixed paraffin-embedded tissue sections from each of the 253 patients treated with radical prostatectomy. Immunohistochemistry scores were obtained by automated image analysis for CCNB1 and PTTG1. Recurrence, defined as locoregional recurrence, distant metastasis or death from prostate cancer, was used as endpoint for survival analysis. Tumors having both positive and negative tumor areas for cytoplasmic BUB3 (30%), CCNB1 (28%), or PTTG1 (35%) were considered heterogeneous. Patients with ≥1 positive tumor area had significantly increased risk of disease recurrence in univariable analysis compared with patients where all tumor areas were negative for cytoplasmic BUB3 (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.41-3.36), CCNB1 (HR = 2.98, 95% CI 1.93-4.61) and PTTG1 (HR = 1.91, 95% CI 1.23-2.97). Combining the scores of cytoplasmic BUB3 and CCNB1 improved risk stratification when integrated with the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score (difference in concordance index = 0.024, 95% CI 0.001-0.05). In analysis of multiple tumor areas, prognostic value was observed for cytoplasmic BUB3, CCNB1, and PTTG1.

PMID:
31801961
DOI:
10.1038/s41379-019-0418-2

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for Norwegian BIBSYS system
Loading ...
Support Center